Investigation of HER-2 status, treatment response and survival analysis in cervical cancer patients

Anti-HER2 therapy has shown benefit in breast and gastric cancers that over-express HER2; therefore, it is critical to determine whether HER2 is over-expressed and amplified in cervical cancer with current FDA-approved tests, as previous works have reported frequencies of over-expression varying from 0% to 77%. We analyzed 100 consecutive patients starting in January 2013. Patients were previously untreated and diagnosed with locally advanced cervical cancer. They received chemoradiation as definitive treatment. We analyzed their primary tumors with HercepTest and HER-2/neu FISH probe, observing a strong adherence to the testing and reporting recommendations for HER2 testing in breast cancer by the American Society of Clinical Oncology. Among 100 patients, accrued 88 had both tests performed. We found 26 (29.5%) FISH-positive cases. HercepTest scores rating 0+, 1+, 2+, and 3+ were observed in 65.3%, 11.5%, 7.6% and 15.3% in the 26 FISH-positive. There was no concordance between the results of both tests using Cohen´s Kappa statistics, neither correlation between FISH status with age, FIGO stage, and response. FISH-positive patients had a non-statistical significant trend for worst 4-year survival. The HER2 protein is over-expressed in only a small subset of invasive cervical cancer as analyzed by Hercept test. Unexpectedly, HER2 gene amplification occurred in around 29.5% of cases. We stress that analyzed HER2 status with the validated methods for the procedures and reports used for breast cancer. Our results must be seen with caution and must encourage further testing in a higher number of patients and different populations to confirm our findings.

Cervical cancer; HER2; Immunohistochemistry; FISH.

[1] Dueñas-Gonzalez A., Cetina L., Coronel J., Cano C., Dolores R.: “New pharmacotherapy options for cervical cancer”. Expert Opin. Pharmacother., 2014, 15, 51-60.

[2] Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Ba-jamonde A., et al.: “Use of chemotherapy plus a monoclonal anti-body against HER2 for metastatic breast cancer that overexpresses HER2”. N. Engl. J. Med., 2001, 344, 783-792.

[3] Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al.: “Trastuzumab after adjuvant chemother-apy in HER2-positive breast cancer”. N. Engl. J. Med., 2005, 353, 1659-1672.

[4] Bang Y., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al.: “Trastuzumab in combination with chemother-apy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial”. Lancet, 2010, 376, 687-697.

[5] Chang J., Tsao Y., Liu D., Han C., Lee W., Chen S.: “The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix”. Gynecol. Oncol., 1999, 73, 62-71.

[6] Gasparian N.A., Pozharisskiĭ K.M., Zharinov G.M., Vinokurov V. L., Kuznetsova M.E., Neklasova N.I.: “Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix”. Vopr. Onkol., 2007, 53, 439-444.

[7] Kihana T., Tsuda H., Teshima S., Nomoto K., Tsugane S., Sonoda T., et al.: “Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix”. Cancer, 1994, 73, 148-153.

[8] Califano D.: “Significance of erb-B2 immunoreactivity in cervical cancer”. Front. Biosci., 2006, 11, 11.

[9] Huang Y.W., Li M.D., Wu Q.L., Liu F.Y.: “Expression and clinical significance of p53 and c-erbB2 in geriatric women with cervical carcinoma. Ai Zheng. 2002, 21, 297-300.

[10] Niibe Y., Watanabe J., Tsunoda S., Arai M., Arai T., Kawaguchi M., et al.: “Concomitant expression of HER2 and HIF-1alpha is a predictor of poor prognosis in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501)”. Eur. J. Gynaecol. Oncol., 2010, 31, 491-496.

[11] Yamashita H., Murakami N., Asari T., Okuma K., Ohtomo K. and Nakagawa K.: “Correlation among six biologic factors (p53, p21WAF1, MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2009, 74, 1165-1172.

[12] Shen L., Shui Y., Wang X., Sheng L., Yang Z., Xue D., et al.: “EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radio-therapy”. BMC Cancer, 2008, 8, 232-232.

[13] Chavez-Blanco A., Perez-Sanchez V., Gonzalez-Fierro A., Vela-Chavez T., Candelaria M., Cetina L., et al.: “HER2 expression in cervical cancer as a potential therapeutic target”. BMC Cancer, 2004, 4, 59.

[14] Lesnikova I., Lidang M., Hamilton-Dutoit S., Koch J.: “HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens”. Apmis, 2009, 117, 737-745.

[15] Mitra A.B., Murty V.V., Pratap M., Sodhani P., Chaganti R.S.: “ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix”. Cancer Res., 1994, 54, 637-639.

[16] Conesa-Zamora P., Torres-Moreno D., Isaac M.A., Pérez-Guillermo M.: “Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence”. Exp. Mol. Pathol., 2013, 95, 151-155.

[17] Mark H.F.L., Feldman D., Das S., Sun C., Samy M., Lathrop J.: “HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization”. Genet. Test., 1999, 3, 237-242.

[18] Bellone S., Palmieri M., Gokden M., Joshua J., Roman J.J., Pecorelli S., et al.: “Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for herceptin-mediated therapy”. Gynecol. Oncol., 2003, 91, 231-240.

[19] Pondé N., Brandão M., El-Hachem G., Werbrouck E., Piccart M.: “Treatment of advanced HER2-positive breast cancer: 2018 and be-yond”. Cancer Treat. Rev., 2018, 67, 10-20.

[20] Hiroshima Y., Zhang Y., Zhao M., Zhang N., Murakami T., Maawy A., et al.: “Tumor-targeting salmonella typhimurium A1-R in combination with trastuzumab eradicates HER-2-Positive cervical cancer cells in patient-derived mouse models”. PLoS One, 2015, 10, e0120358.

[21] Wolff A.C., Hammond M.E.H., Hicks D.G., Dowsett M., Mc-Shane L.M., Allison K.H.: “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update”. J. Clin. Oncol., 2013, 31, 3997-4013.

[22] Golijow C.D., Abba M., Mourón S.A., Gómez M.A., Güercci A., Dulout F.N.: “Detection ofc-erbB-2Gene amplification in cervical scrapes positive for human papillomavirus (HPV)”. Cancer Invest., 2001, 19, 678-683.

[23] Oh D.Y., Kim S., Choi Y.L., Cho Y.J., Oh E, Choi J.J., et al. “HER2 as a novel therapeutic target for cervical cancer”. Oncotarget., 2015, 6, 36219-36230.

[24] Oh D., Bang Y.: “HER2-targeted therapies — a role beyond breast cancer”. Nat. Rev. Clin. Oncol., 2020, 17, 33-48.

[25] White A.E., Livanos E.M., Tlsty T.D.: “Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins”. Genes Dev., 1994, 8, 666-677.

[26] Gao G., Smith D.I.: “Role of the common fragile sites in cancers with a human papillomavirus etiology”. Cytogenet. Genome Res., 2016, 150, 217-226.

[27] Pańczyszyn A., Boniewska-Bernacka E., Głąb G.: “Telomeres and telomerase during human papillomavirus-induced carcinogenesis”. Expert. Rev. Mol. Diagn., 2018, 22, 421-430.

[28] Kaur G., Balasubramaniam S.D., Lee Y.J., Balakrishnan V., Oon C. E.: “Minichromosome maintenance complex (MCM) genes profiling and MCM2 protein expression in cervical cancer development”. Asian Pac. J. Cancer Prev., 2019, 20, 3043-3049.

[29] Couturier J., Vincent-Salomon A., Nicolas A., Beuzeboc P., Mouret E., Zafrani B., et al.: “Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma”. Mod. Pathol., 2000, 13, 1238-1243.

[30] Ridolfi R.L., Jamehdor M.R., Arber J.M.: “HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach”. Mod. Pathol., 2000, 13, 866-873.

[31] Rüschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., et al.: “HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing”. Virchows Arch., 2010, 457, 299-307.

[32] Shi Z., Barna M.: “Translating the genome in time and space: specialized ribosomes, RNA regulons, and RNA-binding proteins”. Annu. Rev. Cell Dev. Biol., 2015, 31, 31-54.

[33] Baiocchi G., Begnami, Chen M.J., Fukazawa E.M., Badiglian-Filho L., Pellizzon A.C.A., et al.: “HER-2 expression and response to radiotherapy in patients with advanced cervical cancer”. J. Reprod. Med., 2018, 62, 234-240.

[34] Lee C.M., Shrieve D.C., Zempolich K.A., Lee R.J., Hammond E., Handrahan D.L., et al.: “Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix”. Gynecol. Oncol., 2005, 99, 415-421.

[35] Kim Y.T., Kim S.W., Yoon B.S.: “Expression of c-erbB-2 oncoprotein and the prognosis of patients with cervical carcinoma”. Int. J. Gynaecol. Obstet., 2006, 92, 151-152.

[36] Kristensen G.B., Holm R., Abeler V.M., Tropé C.G.: “Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma: An immunohistochemical study”. Cancer, 1996, 78, 433-440.

[37] Leung T., Cheung A., Cheng D., Wong L., Ngan H.: “Expressions of c-erbB-2, epidermal growth factor receptor and panras proto-oncogenes in adenocarcinoma of the cervix: Correlation with clinical prognosis”. Oncol. Rep., 2001, 8,1159-64.

[38] Ndubisi B., Sanz S., Lu L., Podczaski E., Benrubi G., Masood S.: “The prognostic value of HER-2/neu oncogene in cervical cancer”. Ann. Clin. Lab. Sci., 1998, 27, 396-401.

[39] Ojesina A.I., Lichtenstein L., Freeman S.S., Pedamallu C.S., Imaz-Rosshandler I., Pugh T.J. et al.: “Landscape of genomic alterations in cervical carcinomas”. Nature, 2014, 506, 371-375.

[40] Connell C.M., Doherty G.J.: “Activating HER2 mutations as emerging targets in multiple solid cancers”. ESMO Open, 2017, 2, e000279.